Journal Mobile Options
Table of Contents
Vol. 53, No. 2, 2006
Issue release date: April 2006
Neuropsychobiology 2006;53:108–112

Atypical Antipsychotic Usage-Related Higher Serum Leptin Levels and Disabled Lipid Profiles in Euthymic Bipolar Patients

Gergerlioglu H.S. · Savas H.A. · Celik A. · Savas E. · Yumru M. · Tarakcioglu M. · Gergerlioglu N. · Atmaca M.
Departments of aPhysiology, bPsychiatry, and cBiochemistry, Medical Faculty, Gaziantep University, and Departments of dInternal Medicine, and ePathology, Av. Cengiz Gokcek State Hospital, Gaziantep, and fDepartment of Psychiatry, Medical Faculty, Firat University, Elazig, Turkey

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Atypical antipsychotics (AA)-induced weight gain is associated with increased leptin levels. AA have been increasingly used in the treatment of bipolar disorders. This cross-sectional study aimed to evaluate the association between serum leptin and lipid profiles considering the drug treatments in euthymic bipolar outpatients. Leptin and lipid profiles were compared, and no differences were noted in leptin, cholesterol, and low-density lipoprotein levels among the patients and controls. Glucose, very-low-density lipoprotein, and triglyceride levels in patients were higher than in controls, while high-density lipoprotein levels were low. Patients were divided into three groups according to their type of drug usage: AA users, AA + mood stabilizer users, and mood stabilizer users. Each group of patients was compared with a healthy control group for mentioned biochemical parameters. Lipid profiles were disordered by using both AA and mood stabilizers, but higher leptin levels are associated with AA usage. However, leptin does not seem to be responsible for dyslipidemia caused by AA or mood stabilizers in euthymic bipolar patients.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Prolo P, Wong ML, Licino J: Leptin. Int J Biochem Cell Biol 1998;30:1285–1290.
  2. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425–432.
  3. Spiegelman BM, Flier JS: Obesity and the regulation of energy balance. Cell 2001;104:531–543.
  4. Sahu A: Minireview: a hypothalamic role in energy balance with special emphasis on leptin. Endocrinology 2004;145:2613–2620.
  5. Elmquist JK, Elias CR, Saper CB: From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 1999;22:221–232.
  6. Uehara Y, Shimizu H, Ohtani K, Sato N, Mori M: Hypothalamic corticotropin-releasing hormone is a mediator of the anorexigenic effect of leptin. Diabetes 1998;47:890–893.
  7. Considine RV, Caro JF: Leptin and regulation of body weight. Int J Biochem Cell Biol 1997;29:1255–1272.
  8. Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH: Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004;184:496–502.
  9. Deuschle M, Blum WF, Englaro P, Schweiger U, Weber B, Pflaum CD, Heuser I: Plasma leptin in depressed patients and healthy controls. Horm Metab Res 1996;28:714–717.
  10. Auwerx J, Steals B: Leptin. Lancet 1998;351:737–742.
  11. Zukowska-Grojec Z: Neuropeptid I: a novel sympathetic stress hormone and more. Ann NY Acad Sci 1995;771:219–233.
  12. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Kennedy SH: Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord 2003;5:28–35.
  13. Comings DE, Gade R, MacMurray JP, Muhleman D, Peters WR: Genetic variants of the human obesity (OB) gene: association with body mass index in young women, psychiatric symptoms, and interaction with the dopamine D2 receptor (DRD2) gene. Mol Psychiatry 1996;1:325–335.
  14. Ertugrul A, Meltzer HY: Antipsychotic drugs in bipolar disorder. Int J Neuropsychopharmacol 2003;6:277–284.
  15. Hirschfeld RM: The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry 2003;64(suppl 8):15–21.

    External Resources

  16. Yatham LN: Efficacy of atypical antipsychotics in mood disorders. J Clin Psychopharmacol 2003;23(suppl 1):9–14.

    External Resources

  17. Yatham LN: Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disord 2003;5(suppl 2):7–19.
  18. Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L: Antipsychotics in bipolar disorders. Encephale 2004;30:417–424.
  19. McCormack PL, Wiseman LR: Olanzapine: a review of its use in the management of bipolar I disorder. Drugs 2004;64:2709–2726.
  20. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR: Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs mood stabiliser alone. Br J Psychiatry 2004;184:337–345.
  21. Atmaca M, Kuloglu M, Tezcan E, Ustundag B: Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64:598–604.
  22. McIntyre RS, Mancini DA, Basile VS, Srinivasan J, Kennedy SH: Antipsychotic-induced weight gain: bipolar disorder and leptin. Clin Psychopharmacol 2003;23:323–327.
  23. Melkersson K, Dahl ML: Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64:701–723.
  24. McIntyre RS, McCann SM, Kennedy SH: Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46:273–281.
  25. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B: Serum cholesterol and leptin levels in patients with borderline personality disorder. Neuropsychobiology 2002;45:167–171.
  26. Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Gecici O, Firidin B: Serum leptin and cholesterol values in the suicide attempters. Neuropsychobiology 2002;45:124–127.
  27. Atmaca M, Kuloglu M, Tezcan E, Ustundag B: Serum cholesterol and leptin levels in patients with bipolar disorders. Neuropsychobiology 2002;46:176–179.
  28. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B: Weight gain, serum leptin and triglyceride levels in the patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res 2003;60:99–100.
  29. Kraus T, Haack M, Schuld A, Hinze-Selch D, Pollmacher T: Low leptin levels but normal body mass indices in patients with depression or schizophrenia. Neuroendocrinology 2001;73:243–247.
  30. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 2004.
  31. Jensen HV, Plenge P, Mellerup ET, Davidsen K, Toftegaard L, Aggernaes H, Bjorum N: Lithium prophylaxis of manic-depressive disorder: daily lithium dosing schedule versus every second day. Acta Psychiatr Scand 1995;92:69–74.
  32. Dogan E, Erkoc R, Eryonucu B, Sayarlioglu H, Agargun MY: Relation between depression, some laboratory parameters, and quality of life in hemodialysis patients. Ren Fail 2005;27:695–699.
  33. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, Pollmacher T: Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999;156:312–314.
  34. Sequist TD, Bates DW, Cook EF, Lampert S, Schaefer M, Wright J, Sato L, Lee TH: Prediction of missed myocardial infarction among symptomatic outpatients without coronary heart disease. Am Heart J 2005;149:74–81.
  35. Klumpers UM, Boom K, Janssen FM, Tulen JH, Loonen AJ: Cardiovascular risk factors in outpatients with bipolar disorder. Pharmacopsychiatry 2004;37:211–216.
  36. Luef G, Abraham I, Hoppichler F, Trinka E, Unterberger I, Bauer G, Lechleitner M: Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 2002;51:1274–1278.
  37. Himmerich H, Koethe D, Yassuridis A, Pollmacher T: Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology 2005;179:447–451.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50